Hepatitis C NS5A protein: Two drug targets within the same protein with different mechanisms of resistance

Current Opinion in Virology

Volumn 8, Issue , 2014, Pages 30-37

  Lim, Precious J ^a   Gallay, Philippe A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; CYCLOPHILIN INHIBITOR; DACLATASVIR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BMS-790052; CYCLOSPORIN; FLUORENE DERIVATIVE; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; PROTEIN BINDING; VIRAL PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CROSS RESISTANCE; DRUG POTENCY; DRUG RESPONSE; DRUG TARGETING; HALF LIFE TIME; HEPATITIS C; HUMAN; MUTATION RATE; NONHUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; RNA REPLICATION; TURNOVER TIME; VIRUS INHIBITION; VIRUS MUTATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; HEPACIVIRUS; METABOLISM; MISSENSE MUTATION;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYCLOSPORINE; DRUG RESISTANCE, VIRAL; FLUORENES; HEPACIVIRUS; HUMANS; IMIDAZOLES; MUTATION, MISSENSE; PROTEIN BINDING; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84901687280     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.04.012     Document Type: Review

References (73)

1. A. Macdonald, and M. Harris Hepatitis C virus NS5A: tales of a promiscuous protein J Gen Virol 85 2004 2485 2502 (Pubitemid 39214345)
2. Y. He, K. Staschke, and S.L. Tan HCV NS5A: a multifunctional regulator of cellular pathways and virus replication S.L. Tan, Hepatitis C Virus: Genome and Molecular Biology 2006 Horizon Bioscience 267 292
3. V. Brass, E. Bieck, R. Montserret, B. Wolk, J.A. Hellings, H.E. Blum, F. Penin, and D. Moradpour An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A J Biol Chem 277 2002 8130 8139 (Pubitemid 34968267)
4. T.L. Tellinghuisen, J. Marcotrigiano, A.E. Gorbalenya, and C.M. Rice The NS5A protein of hepatitis C virus is a zinc metalloprotein J Biol Chem 279 2004 48576 48587 (Pubitemid 39625732)
5. T.L. Tellinghuisen, K.L. Foss, J.C. Treadaway, and C.M. Rice Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein J Virol 82 2008 1073 1083
6. Y. Liang, H. Ye, C.B. Kang, and H.S. Yoon Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded Biochemistry 46 2007 11550 11558 (Pubitemid 47585500)
7. X. Hanoulle, D. Verdegem, A. Badillo, J.M. Wieruszeski, F. Penin, and G. Lippens Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded Biochem Biophys Res Commun 381 2009 634 638
8. X. Hanoulle, A. Badillo, D. Verdegem, F. Penin, and G. Lippens The domain 2 of the HCV NS5A protein is intrinsically unstructured Protein Pept Lett 17 2010 1012 1018
9. L. Huang, J. Hwang, S.D. Sharma, M.R. Hargittai, Y. Chen, J.J. Arnold, K.D. Raney, and C.E. Cameron Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein J Biol Chem 280 2005 36417 36428 (Pubitemid 41633916)
10. T.L. Foster, T. Belyaeva, N.J. Stonehouse, A.R. Pearson, and M. Harris All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding J Virol 84 2010 9267 9277
11. U. Chatterji, P. Lim, M.D. Bobardt, S. Wieland, D.G. Cordek, G. Vuagniaux, F. Chisari, C.E. Cameron, P. Targett-Adams, and T. Parkinson et al. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors J Hepatol 53 2010 50 56
12. B. de Chassey, V. Navratil, L. Tafforeau, M.S. Hiet, A. Aublin-Gex, S. Agaugue, G. Meiffren, F. Pradezynski, B.F. Faria, and T. Chantier et al. Hepatitis C virus infection protein network Mol Syst Biol 4 2008 230
13. T.L.F.K. Tellinghuisen, and J.C. Treadaway Regulation of hepatitis C virion production via phosphorylation of the NS5A protein PLoS Pathog 4 2008 e1000032
14. N. Appel, M. Zayas, S. Miller, J. Krijnse-Locker, T. Schaller, P. Friebe, S. Kallis, U. Engel, and R. Bartenschlager Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly PLoS Pathog 4 2008 e1000035
15. T.L. Tellinghuisen, J. Marcotrigiano, and C.M. Rice Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase Nature 435 2005 374 379 (Pubitemid 40745549)
16. R.A. Love, O. Brodsky, M.J. Hickey, P.A. Wells, and C.N. Cronin Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus J Virol 83 2009 4395 4403
17. J. Hwang, L. Huang, D.G. Cordek, R. Vaughan, S.L. Reynolds, G. Kihara, K.D. Raney, C.C. Kao, and C.E. Cameron Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins J Virol 84 2010 12480 12491
18. N. Appel, T. Schaller, F. Penin, and R. Bartenschlager From structure to function: new insights into hepatitis C virus RNA replication J Biol Chem 281 2006 9833 9836 (Pubitemid 43864513)
19. M. Binder, N. Sulaimanov, D. Clausznitzer, M. Schulze, C.M. Huber, S.M. Lenz, J.P. Schloder, M. Trippler, R. Bartenschlager, and V. Lohmann et al. Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle PLoS Pathog 9 2013 e1003561
20. D. Egger, B. Wolk, R. Gosert, L. Bianchi, H.E. Blum, D. Moradpour, and K. Bienz Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex J Virol 76 2002 5974 5984 (Pubitemid 34556292)
21. I. Romero-Brey, A. Merz, A. Chiramel, J.Y. Lee, P. Chlanda, U. Haselman, R. Santarella-Mellwig, A. Habermann, S. Hoppe, and S. Kallis et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication PLoS Pathog 8 2012 e1003056
22. T.K. Scheel, and C.M. Rice Understanding the hepatitis C virus life cycle paves the way for highly effective therapies Nat Med 19 2013 837 849
23. P. Simmonds The origins of hepatitis C virus R. Bartenschlager, Hepatitis C Virus: From Molecular Virology to Antiviral Therapy 2013 Springer 1 15
24. O. Belda, and P. Targett-Adams Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein Virus Res 170 2012 1 14
25. D. Hernandez, N. Zhou, J. Ueland, A. Monikowski, and F. McPhee Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors J Clin Virol 57 2013 13 18
26. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, R.A. Fridell, M.H. Serrano-Wu, D.R. Langley, J.H. Sun, and D.R. O'Boyle II et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
27. R.A. Fridell, D. Qiu, C. Wang, L. Valera, and M. Gao Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob Agents Chemother 54 2010 3641 3650
28. R.A. Fridell, D. Qiu, L. Valera, C. Wang, R.E. Rose, and M. Gao Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 J Virol 85 2011 7312 7320
29. T.K. Scheel, J.M. Gottwein, L.S. Mikkelsen, T.B. Jensen, and J. Bukh Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha Gastroenterology 140 2011 1032 1042
30. M. Gao Antiviral activity and resistance of HCV NS5A replication complex inhibitors Curr Opin Virol 3 2013 514 520
31. J.O. Link, J.G. Taylor, L. Xu, M. Mitchell, H. Guo, H. Liu, D. Kato, T. Kirschberg, J. Sun, and N. Squires et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection J Med Chem 57 2014 2033 2046
32. R.E. Nettles, M. Gao, M. Bifano, E. Chung, A. Persson, T.C. Marbury, R. Goldwater, M.P. DeMicco, M. Rodriguez-Torres, and A. Vutikullird et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Hepatology 54 2011 1956 1965
33. E.J. Lawitz, D. Gruener, J.M. Hill, T. Marbury, L. Moorehead, A. Mathias, G. Cheng, J.O. Link, K.A. Wong, and H. Mo et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C J Hepatol 57 2012 24 31
34. J. Guedj, H. Dahari, L. Rong, N.D. Sansone, R.E. Nettles, S.J. Cotler, T.J. Layden, S.L. Uprichard, and A.S. Perelson Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc Natl Acad Sci U S A 110 2013 3991 3996
35. J. Paeshuyse, A. Kaul, E. De Clercq, B. Rosenwirth, J.M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 43 2006 761 770
36. S. Hopkins, B. Scorneaux, Z. Huang, M.G. Murray, S. Wring, C. Smitley, R. Harris, F. Erdmann, G. Fischer, and Y. Ribeill SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro Antimicrob Agents Chemother 54 2010 660 672
37. F. Yang, J.M. Robotham, H.B. Nelson, A. Irsigler, R. Kenworthy, and H. Tang Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro J Virol 82 2008 5269 5278 (Pubitemid 351705235)
38. H. Waller, U. Chatterji, P. Gallay, T. Parkinson, and P. Targett-Adams The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A J Virol Methods 165 2010 202 210
39. L. Coelmont, X. Hanoulle, U. Chatterji, C. Berger, J. Snoeck, M. Bobardt, P. Lim, I. Vliegen, J. Paeshuyse, and G. Vuagniaux et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PLoS ONE 5 2010 e13687
40. J.A. Garcia-Rivera, M. Bobardt, U. Chatterji, S. Hopkins, M.A. Gregory, B. Wilkinson, K. Lin, and P.A. Gallay Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir Antimicrob Agents Chemother 56 2012 5113 5121
41. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, and A.S. Perelson Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107 (Pubitemid 28471138)
42. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra32
43. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
44. J. Vermehren, and C. Sarrazin The role of resistance in HCV treatment Best Pract Res Clin Gastroenterol 26 2012 487 503
45. J.M. Pawlotsky Hepatitis C virus: standard-of-care treatment E. de Clercq, Advances in Pharmacology vol 67 2013 Elsevier 169 215
46. M.H. Powdrill, E.P. Tchesnokov, R.A. Kozak, R.S. Russell, R. Martin, E.S. Svarovskaia, H. Mo, R.D. Kouyos, and M. Gotte Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance Proc Natl Acad Sci U S A 108 2011 20509 20513
47. C. Welsch, and S. Zeuzem Clinical relevance of HCV antiviral drug resistance Curr Opin Virol 2 2012 651 655
48. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
49. R.A. Fridell, C. Wang, J.H. Sun, D.R. O'Boyle II, P. Nower, L. Valera, D. Qiu, S. Roberts, X. Huang, and B. Kienzle et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatology 54 2011 1924 1935
50. C. Wang, J.H. Sun, D.R. O'Boyle II, P. Nower, L. Valera, S. Roberts, R.A. Fridell, and M. Gao Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir Antimicrob Agents Chemother 57 2013 2054 2065
51. J.H. Sun, D.R. O'Boyle Ii, Y. Zhang, C. Wang, P. Nower, L. Valera, S. Roberts, R.E. Nettles, R.A. Fridell, and M. Gao Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052 Hepatology 55 2012 1692 1699
52. F. McPhee, T.J. Chayama, K. Miyagoshi, H. Tamura e, H. Ishikawa, E. Hughes, D. Hernandez, and H. Kumada Analysis of HCV resistant variants in a phase 3 trial of daclatasvir combined with asunaprevir for Japanese patients with genotype 1b infection Hepatology 58 2013 749A
53. H. Kumada, Y. Suzuki, K. Ikeda, J. Toyota, Y. Karino, K. Chayama, Y. Kawakami, A. Ido, K. Yamamoto, and K. Takaguchi et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection Hepatology 2014 10.1002/hep.27113
54. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, I. Jacobson, E. Lawitz, A.S. Lok, F. Hinestrosa, and P.J. Thuluvath et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
55. K.A. Wong, A. Worth, R. Martin, E. Svarovskaia, D.M. Brainard, E. Lawitz, M.D. Miller, and H. Mo Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885 Antimicrob Agents Chemother 57 2013 6333 6340
56. U. Chatterji, M. Bobardt, S. Selvarajah, F. Yang, H. Tang, N. Sakamoto, G. Vuagniaux, T. Parkinson, and P. Gallay The isomerase active site of cyclophilin A is critical for hepatitis C virus replication J Biol Chem 284 2009 16998 17005
57. A. Kaul, S. Stauffer, C. Berger, T. Pertel, J. Schmitt, S. Kallis, M. Zayas, V. Lohmann, J. Luban, and R. Bartenschlager Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics PLoS Pathog 5 2009 e1000546
58. Z. Liu, F. Yang, J.M. Robotham, and H. Tang Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex J Virol 83 2009 6554 6565
59. F. Yang, J.M. Robotham, H. Grise, S. Frausto, V. Madan, M. Zayas, R. Bartenschlager, M. Robinson, A.E. Greenstein, and A. Nag et al. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach PLoS Pathog 6 2010 e1001118
60. U. Chatterji, M.D. Bobardt, P. Lim, and P.A. Gallay Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes J Gen Virol 91 2010 1189 1193
61. F. Fernandes, I.U. Ansari, and R. Striker Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A PLoS ONE 5 2010 e9815
62. M.A. Gregory, M. Bobardt, S. Obeid, U. Chatterji, N.J. Coates, T. Foster, P. Gallay, P. Leyssen, S.J. Moss, and J. Neyts et al. Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family Antimicrob Agents Chemother 55 2011 1975 1981
63. S. Hopkins, M. Bobardt, U. Chatterji, J.A. Garcia-Rivera, P. Lim, and P.A. Gallay The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes Antimicrob Agents Chemother 56 2012 3888 3897
64. J.Y.J. Guedj, M. Levi, B. Li, S. Kern, N.V. Naoumov, and A.S. Perelson Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients Hepatology 2013 10.1002/hep.26989
65. R. Flisiak, A. Horban, P. Gallay, M. Bobardt, S. Selvarajah, A. Wiercinska-Drapalo, E. Siwak, I. Cielniak, J. Higersberger, and J. Kierkus et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Hepatology 47 2008 817 826 (Pubitemid 351449673)
66. H. Grise, S. Frausto, T. Logan, and H. Tang A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility J Virol 86 2012 4811 4822
67. U. Chatterji, J.A. Garcia-Rivera, J. Baugh, K. Gawlik, K.A. Wong, W. Zhong, C.A. Brass, N.V. Naoumov, and P.A. Gallay Alisporivir plus NS5A inhibitor combination provides additive to synergistic anti-HCV activity without detectable cross resistance Antimicrob Agents Chemother 2014 10.1128/AAC.00016-14
68. F. Negro Steatosis and insulin resistance in response to treatment of chronic hepatitis C J Viral Hepat 19 Suppl 1 2012 42 47
69. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, F. Lammert, A. Duarte-Rojo, E.J. Heathcote, M.P. Manns, and L. Kuske et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
70. A. Kau, J. Vermehren, and C. Sarrazin Treatment predictors of a sustained virologic response in hepatitis B and C J Hepatol 49 2008 634 651
71. S.M. Horner, and M. Gale Jr. Regulation of hepatic innate immunity by hepatitis C virus Nat Med 19 2013 879 888
72. R.K.R. Liu, P. Mann, P. Ingravallo, Y. Zhai, E. Xia, S. Ludmerer, J. Kozlowski, and C. Coburn In vitro resistance analysis of HCV NS5A inhibitor MK-8742 demonstrates increased potency against clinical resistance variants and higher resistance barrier J Hepatol 56 2012 S334 S335
73. G.W.J. Yang, D. Patel, Y. Zhao, J. Fabrycki, S. Weinheimer, C. Marlor, J. Rivera, Q. Wang, V. Gadhachanda, and A. Hashimoto et al. Preclinical characteristics of ACH-3102: a novel HCV NS5A inhibitor with improved potency against genotype-1a virus and variants resistant to 1st generation of NS5A inhibitors J Hepatol 56 2012 S330